Douglas Miehm
Stock Analyst at RBC Capital
(3.39)
# 1,168
Out of 4,974 analysts
47
Total ratings
52.38%
Success rate
4.34%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Maintains: Outperform | $7 → $8 | $5.54 | +44.40% | 3 | Aug 26, 2025 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $8 → $9 | $12.40 | -27.42% | 10 | Aug 1, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $7.35 | +36.05% | 20 | May 2, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $18 → $17 | $15.01 | +13.26% | 13 | Apr 4, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $1.06 | +371.70% | 1 | Mar 10, 2025 |
MannKind
Aug 26, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.54
Upside: +44.40%
Aurinia Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $12.40
Upside: -27.42%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $7.35
Upside: +36.05%
Bausch + Lomb
Apr 4, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $15.01
Upside: +13.26%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $1.06
Upside: +371.70%